Skip to content
Screener

Assembly Biosciences ASMB Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$8.2MMiss by $1.1M
EPS-$0.54Beat by $0.19
Revenue estimate$9.3M
EPS estimate-$0.73

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$9.1M
EPS estimate-$0.66

Financials

Q1 2026

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K—
Free cash flow-$22.1M+5.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$440.19M+514%
Enterprise value$411.56M+702%
P/S6.2×+4.0×

Returns & leverage

See full
Debt / equity0×-0.1×
Current ratio6.6×+4.6×

FAQ

When did Assembly Biosciences report Q1 2026 earnings?
Assembly Biosciences (ASMB) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Assembly Biosciences's Q1 2026 revenue and EPS?
Assembly Biosciences reported revenue of $8.2M and eps of $-0.54 for Q1 2026.
Did Assembly Biosciences beat estimates in Q1 2026?
Revenue missed the consensus estimate of $9.3M by $1.1M. EPS beat the consensus estimate of $-0.73 by $0.19.
How did Assembly Biosciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 12.8% from $9.4M a year earlier and eps grew 53.8% from $-1.17.
Where can I find Assembly Biosciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-211922) and the 10-Q periodic report (0001193125-26-211987) directly on SEC EDGAR. The filing index links above go to sec.gov.